CAS 202138-50-9 Tenofovir disoproxil fumarate - Analytical Products / Alfa Chemistry

CAT	AP202138509-A
CAS	202138-50-9
Structure
Molecular Weight	635.51

Description	United States Pharmacopeia (USP) Reference Standard
Size	200MG

1

96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection

Kosh Agarwal, Maurizia Brunetto, Wai Kay Seto, Young-Suk Lim, Scott Fung, Patrick Marcellin, Sang Hoon Ahn, Namiki Izumi, Wan-Long Chuang, Ho Bae, Manoj Sharma, Harry L A Janssen, Calvin Q Pan, Mustafa Kemal Çelen, etc.

J Hepatol. 2018 Apr;68(4):672-681.

PMID: 29756595

1

Is Tenofovir Alafenamide Safer Than Tenofovir Disoproxil Fumarate for the Kidneys?

Blandine Aloy, Imane Tazi, Corinne Isnard Bagnis, Marion Gauthier, Nicolas Janus, Vincent Launay-Vacher, Gilbert Deray, Jérôme Tourret

AIDS Rev. Oct-Dec 2016;18(4):184-192.

PMID: 27438578

1

Tenofovir Alafenamide (TAF) as the Successor of Tenofovir Disoproxil Fumarate (TDF)

Erik De Clercq

Biochem Pharmacol. 2016 Nov 1;119:1-7.

PMID: 27133890

1

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for the Treatment of Patients With HBeAg-negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial

Maria Buti, Edward Gane, Wai Kay Seto, Henry L Y Chan, Wan-Long Chuang, Tatjana Stepanova, Aric-Josun Hui, Young-Suk Lim, Rajiv Mehta, Harry L A Janssen, Subrat K Acharya, John F Flaherty, Benedetta Massetto, etc.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206.

PMID: 28404092

1

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate: Is There a True Difference in Efficacy and Safety?

Andrew Hill, Sophie L Hughes, Dzintars Gotham, Anton L Pozniak

J Virus Erad. 2018 Apr 1;4(2):72-79.

PMID: 29682298

* Products or Services Interested: Tenofovir disoproxil fumarate (202138-50-9)
* Your question
* Name
* Email
Verification Code